Comp34 displays potent preclinical antitumor efficacy in triple-negative breast cancer via inhibition of NUDT3-AS4 a novel oncogenic long noncoding RNA

摘要

a Screening growth-inhibitory effects of 33 curcumin derivatives on MDA-MB-231 cells. b Chemical structure of Comp34. c IC50 values exhibited by Comp34 for cytotoxicity against various breast cancer cell lines and nontumorigenic breast epithelial cells. d Phosphorylation status of 34 kinases or transcription factors was assessed by the proteome profiler human phospho-kinase array. e Relative phosphorylation of spots was quantified by normalizing pixel density of the positive control to 100. f Western blotting (WB) analysis of the expression of AKT1, p-AKT, mTOR, p-p70S6K, p-S6, p-4EBP1 in the MDA-MB-231 cell line upon different concentrations of Comp34 treatment. g Reduction of AKT1 and mTOR mRNA expression in MDA-MB-231 cells treated with Comp34 analyzed by qRT-PCR (n = 3 replicates). *P < 0.05 versus control. h Dissociation of mammospheres after treatment with Comp34. The results represent the mean diameter of mammospheres ± SD, n = 6. i Comp34 reduced the stemness of MDA-MB-231 cells in a dose-dependent manner. Stem cell populations were analyzed by FACS using CD44 and CD24 antibodies. US unstained. The results represent the mean percentage of stem cell population ± SD, n = 6.